TABLE OF CONTENTS
Volume 26, Issue 25 (28 May 2007)
Guest Editor
Top of pageIntroduction
Preface: antibody therapies for cancer
B Bonavida
Oncogene 26: 3592-3593; doi:10.1038/sj.onc.1210369
Reviews
Anti-idiotype antibodies in cancer treatment
A López-Díaz de Cerio, N Zabalegui, M Rodríguez-Calvillo, S Inogés and M Bendandi
Oncogene 26: 3594-3602; doi:10.1038/sj.onc.1210371
Rituximab therapy in malignant lymphoma
B Coiffier
Oncogene 26: 3603-3613; doi:10.1038/sj.onc.1210376
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab
A J Davies
Oncogene 26: 3614-3628; doi:10.1038/sj.onc.1210378
'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'
B Bonavida
Oncogene 26: 3629-3636; doi:10.1038/sj.onc.1210365
Trastuzumab: triumphs and tribulations
R Nahta and F J Esteva
Oncogene 26: 3637-3643; doi:10.1038/sj.onc.1210379
Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
L Alinari, R Lapalombella, L Andritsos, R A Baiocchi, T S Lin and J C Byrd
Oncogene 26: 3644-3653; doi:10.1038/sj.onc.1210380
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
G Galizia, E Lieto, F De Vita, M Orditura, P Castellano, T Troiani, V Imperatore and F Ciardiello
Oncogene 26: 3654-3660; doi:10.1038/sj.onc.1210381
Current role of antibody therapy in patients with metastatic colorectal cancer
P Pfeiffer, C Qvortrup and J G Eriksen
Oncogene 26: 3661-3678; doi:10.1038/sj.onc.1210377
The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
L Pagano, L Fianchi, M Caira, S Rutella and G Leone
Oncogene 26: 3679-3690; doi:10.1038/sj.onc.1210364
Bevacizumab in the treatment of non-small-cell lung cancer
T E Stinchcombe and M A Socinski
Oncogene 26: 3691-3698; doi:10.1038/sj.onc.1210366
Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma
T A Waldmann
Oncogene 26: 3699-3703; doi:10.1038/sj.onc.1210368
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies
J P Leonard and D M Goldenberg
Oncogene 26: 3704-3713; doi:10.1038/sj.onc.1210370
Novel antibodies as anticancer agents
I Zafir-Lavie, Y Michaeli and Y Reiter
Oncogene 26: 3714-3733; doi:10.1038/sj.onc.1210372
Novel radiolabeled antibody conjugates
D M Goldenberg and R M Sharkey
Oncogene 26: 3734-3744; doi:10.1038/sj.onc.1210373
Targeting death-inducing receptors in cancer therapy
K Takeda, J Stagg, H Yagita, K Okumura and M J Smyth
Oncogene 26: 3745-3757; doi:10.1038/sj.onc.1210374
